Kodiak(US:KOD) ZACKSยท2025-09-12 16:31Company Overview - Kodiak Sciences Inc. reported a loss of $1.03 per share in Q2 2025, which was wider than the Zacks Consensus Estimate of a loss of $1.01, and compared to a loss of $0.86 per share in the same quarter last year [2] - The company currently has no approved products and has not generated any revenues [2] Financial Performance - Research and development expenses for the reported quarter were $42.8 million, reflecting a 32% increase year-over-year due to heightened clinical activities [3] - General and administrative expenses decreased to $12.8 million, down 18% year-over-year, primarily due to lower non-cash stock-based compensation expenses [3] - As of June 30, 2025, Kodiak had cash, cash equivalents, and marketable securities totaling $104.2 million, down from $138.9 million as of March 31, 2025, which the company believes is sufficient to support operations into 2026 [4] Market Sentiment - There has been a downward trend in estimates for Kodiak Sciences, with the consensus estimate shifting down by 14.44% over the past month [5] - The stock has a Growth Score of B but is rated F for Momentum and D for Value, resulting in an aggregate VGM Score of F [6] Industry Comparison - Kodiak Sciences is part of the Zacks Medical - Biomedical and Genetics industry, where Exact Sciences (EXAS) has seen a 24.5% gain over the past month, reporting revenues of $811.09 million for the last quarter, a 16% year-over-year increase [8] - Exact Sciences is expected to post earnings of $0.10 per share for the current quarter, indicating a 147.6% change from the year-ago quarter, with a Zacks Rank of 3 (Hold) [9]